Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Equity Average (2021 - 2025)

Historic Equity Average for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $88.5 million.

  • SAB Biotherapeutics' Equity Average rose 11330.46% to $88.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.5 million, marking a year-over-year increase of 11330.46%. This contributed to the annual value of $41.6 million for FY2024, which is 575.91% down from last year.
  • SAB Biotherapeutics' Equity Average amounted to $88.5 million in Q3 2025, which was up 11330.46% from $16.7 million recorded in Q2 2025.
  • SAB Biotherapeutics' Equity Average's 5-year high stood at $88.5 million during Q3 2025, with a 5-year trough of $16.7 million in Q2 2025.
  • For the 5-year period, SAB Biotherapeutics' Equity Average averaged around $37.2 million, with its median value being $36.7 million (2021).
  • Its Equity Average has fluctuated over the past 5 years, first surged by 13739.49% in 2024, then tumbled by 6621.87% in 2025.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Equity Average stood at $36.8 million in 2021, then decreased by 16.23% to $30.8 million in 2022, then grew by 17.63% to $36.3 million in 2023, then dropped by 13.35% to $31.4 million in 2024, then skyrocketed by 181.67% to $88.5 million in 2025.
  • Its last three reported values are $88.5 million in Q3 2025, $16.7 million for Q2 2025, and $23.7 million during Q1 2025.